ESR1 and breast carcinoma: Hence, AMPC inhibition of TFF3 has the added advantage of abrogating the remaining low level of HER signalling in the trastuzumab resistant HER2+/ER+ breast cancer cells such that eradication of these resistant cells did not require re-sensitization to trastuzumab.